Other Events ·
Genmab reports petosemtamab combo cuts death risk by 50% in Phase 3 head and neck cancer trial
GNMSFGenmab A/S
Genmab announced positive topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab, an investigational bispecific antibody, in combination with pembrolizumab versus pembrolizumab alone. Based on a first interim analysis by an independent data monitoring committee, the treatment met both primary endpoints of overall survival and objective response rate in patients with first-line PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma. The combination reduced the risk of death by 50% (HR 0.50) and demonstrated a statistically significant improvement in objective response rate (odds ratio 3.17). The safety profile was generally well tolerated with no new signals identified. Genmab plans to engage global regulatory authorities and submit full results for presentation at a future medical meeting. Genmab is an international biotechnology company dedicated to developing innovative antibody medicines for cancer.